01 March 2024
ReNeuron Group plc
("ReNeuron" or the "Company")
Block Listing Review
and Total Voting Rights
ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.
|
Name: |
ReNeuron Group plc |
|
Name of Scheme: |
ReNeuron Share Option Schemes |
|
Period of Return: |
From 1 September 2023 to 29 February 2024 |
|
Balance of unallotted securities under scheme(s) from previous return: |
8,600,000 Ordinary Shares (of 1p each)
|
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last Review (if any increase has been applied for): |
- |
|
Less: Number of securities issued/allotted under scheme(s) during period |
- |
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
8,600,000 Ordinary Shares |
|
Number and class of securities originally admitted and the date of admission: |
20,000 ordinary shares on 13 May 2010 |
Total Voting Rights
At 29 February 2024, the Company had 57,173,760 Ordinary Shares in issue, each carrying one voting right.
As the Company holds no ordinary shares in treasury, the figure of 57,173,760 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
ENDS
Contacts:
|
ReNeuron |
|
|
|
Iain Ross, Executive Chairman |
Via Walbrook PR |
|
|
John Hawkins, Chief Financial Officer |
|
|
|
|
|
|
|
Allenby Capital Limited (Nominated Adviser and Broker) |
+44 (0)20 3328 5656 |
|
|
James Reeve/George Payne/Dan Dearden-Williams (Corporate Finance) |
|
|
|
Stefano Aquilino/Kelly Gardiner (Sales & Corporate Broking) |
|
|
|
|
|
|
|
Walbrook PR (Media & Investor Relations) |
+44 (0)20 7933 8780 or reneuron@walbrookpr.com |
|
|
Paul McManus / Alice Woodings |
+44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
About ReNeuron
ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.
Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
